+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Macular Edema - Pipeline Review, H2 2019

  • ID: 4901304
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 87 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Anew Oncology Inc
  • Celon Pharma SA
  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mabion SA
  • PharmAbcine Inc
  • MORE
Macular Edema - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2019, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 2, 12, 1 and 1 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Anew Oncology Inc
  • Celon Pharma SA
  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mabion SA
  • PharmAbcine Inc
  • MORE
Introduction
Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema - Companies Involved in Therapeutics Development
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Profarma
Promedior Inc
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
Macular Edema - Drug Profiles
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Macular Edema, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Macular Edema - Pipeline by Anew Oncology Inc, H2 2019
Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H2 2019
Macular Edema - Pipeline by Celon Pharma SA, H2 2019
Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2019
Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2019
Macular Edema - Pipeline by Formycon AG, H2 2019
Macular Edema - Pipeline by Lupin Ltd, H2 2019
Macular Edema - Pipeline by Luye Pharma Group Ltd, H2 2019
Macular Edema - Pipeline by Mabion SA, H2 2019
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H2 2019
Macular Edema - Pipeline by PharmAbcine Inc, H2 2019
Macular Edema - Pipeline by Profarma, H2 2019
Macular Edema - Pipeline by Promedior Inc, H2 2019
Macular Edema - Pipeline by Sustained Nano Systems LLC, H2 2019
Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H2 2019
Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H2 2019
Macular Edema - Pipeline by Tarsius Pharma Ltd, H2 2019
Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2019
Macular Edema - Dormant Projects, H2 2019
Macular Edema - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Macular Edema, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Anew Oncology Inc
  • AsclepiX Therapeutics Inc
  • Celon Pharma SA
  • Clearside BioMedical Inc
  • Coherus BioSciences Inc
  • Formycon AG
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Mabion SA
  • OMEICOS Therapeutics GmbH
  • PharmAbcine Inc
  • Profarma
  • Promedior Inc
  • Sustained Nano Systems LLC
  • Taiwan Liposome Co Ltd
  • Targeted Therapy Technologies LLC
  • Tarsius Pharma Ltd
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
Adroll
adroll